Q2 2026 revenue rose 12% year-over-year to $3.3B, led by CF, CASGEVY, and JOURNAVX growth. Guidance for 2026 revenue was raised to $13.1–$13.2B, with at least $500M expected from non-CF products. The Crinetics acquisition and multiple regulatory milestones position the company for continued expansi…
Biotech company Vertex Pharmaceuticals NASDAQ:VRTX announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73…
Q2 2026 saw 12% revenue growth, driven by CF and new product launches, with strong global uptake and expanded access. Full-year revenue guidance was raised, and the $10B Crinetics acquisition will add a fifth disease area. Cash reserves remain robust at $13.6B.Original document: Vertex Pharmaceutic…
Biotech company Vertex Pharmaceuticals NASDAQ:VRTXwill be reporting results this Monday after the bell. Here’s what to look for.Vertex Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $2.99 billion, up 8.2% year on year. It was a mixed quarter for the company…
WSW, NY, July 23rd, 2026, FinanceWireNuvectis Pharma NASDAQ:NVCT announced this morning that ciprocopan (NXP100) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously re…
WSW, NY, July 22nd, 2026, FinanceWireTen billion dollars. That is what Vertex Pharmaceuticals (Nasdaq: VRTX) agreed to pay on July 6, 2026, to acquire Crinetics Pharmaceuticals (Nasdaq: CRNX) at $85.00 per share, roughly a 101% premium to the prior close.Consider what Vertex is buying: PALSONIFY, t…
WSW, NY, July 9th, 2026, FinanceWireIn June, Nuvectis Pharma NASDAQ:NVCT signed a deal that took it from a single-drug oncology company to the owner of one of the more closely watched assets in rare-disease medicine: NXP100, a once-a-day pill for a blood disorder called paroxysmal nocturnal hemoglo…
Issued on behalf of Avaí Bio, Inc.As cell-based medicine moves from the lab toward the clinic across diabetes, transplant, and aging, Avaí Bio and partner Austrianova have banked the genetically modified cells that will manufacture their encapsulated alpha-Klotho productLAS VEGAS, July 8, 2026 /PRN…
Vertex Pharmaceuticals’ (VRTX) acquisition of Crinetics Pharmaceuticals (CRNX) has turned the spotlight back on mid-cap biotech, where Viking Therapeutics’ (VKTX) obesity pipeline and BioCryst Pharmaceuticals’ (BCRX) rare-disease platform are drawing fresh takeover buzz.VKTX stock jumped 9% on Tues…
Vertex Pharmaceuticals NASDAQ:VRTX fell 0.30% in premarket after the cystic fibrosis and pain drug maker announced an all-cash acquisition of Crinetics Pharmaceuticals NASDAQ:CRNX, a San Diego-based specialty endocrinology company, for $85 per share, or $10 billion in equity value and $8.8 billion…
Vertex Pharmaceuticals' nearly $10 billion buy of Crinetics Pharmaceuticals makes strategic sense, Evercore analysts say in a research note, even if the timing and size of the deal is a bit surprising. The deal shows Vertex continuing to diversify, adding a fifth therapeutic area to its portfolio w…
(11:04 GMT) Vertex Pharmaceuticals Price Target Raised to $350.00/Share From $330.00 by Baird
RNS Number : 3461L Intl. Biotechnology Trust PLC 07 July 2026 INTERNATIONAL BIOTECHNOLOGY TRUST PLC ("IBT")IBT portfolio company Crinetics to be acquired by VertexIBT notes the announcement yesterday that Crinetics Pharmaceuticals (Crinetics) has entered into a definitive agreement to be acquir…
The acquisition brings two best-in-class endocrine assets with blockbuster potential, expanding the acquirer's portfolio and supporting sustained revenue growth. The $10B deal is expected to close in Q3 2026, with strong physician support and significant synergies anticipated.Based on Vertex Pharma…
By Grace YoonVertex Pharmaceuticals has agreed to purchase Crinetics Pharmaceuticals for $10 billion, adding a biopharmaceutical company that specializes in treatments for endocrine diseases to its portfolio that mainly includes cystic fibrosis therapies.Vertex, a Boston-based biotechnology company…
Vertex will acquire Crinetics for $10B in cash, adding best-in-class endocrinology assets with ~$5B peak sales potential. The deal accelerates revenue growth, enhances long-term earnings, and strengthens the specialty endocrinology portfolio.Original document: Vertex Pharmaceuticals Incorporated [V…
VERTEX TO ACQUIRE CRINETICS PHARMACEUTICALSVERTEX TO BUY CRINETICS FOR $85 PER SHARE IN $10 BILLION DEALVERTEX WILL ACQUIRE CRINETICS FOR $85.00 PER SHARE IN CASHVERTEX TO FINANCE
Vertex Pharmaceuticals NASDAQ:VRTX will buy Crinetics Pharmaceuticals NASDAQ:CRNX for a total equity value of about $10 billion, the companies said on Monday, adding treatments for rare hormonal diseases to its portfolio.Vertex's offer of $85 per Crinetics share represents a 102% premium to the sto…
Vertex Pharmaceuticals NASDAQ:VRTX will buy Crinetics Pharmaceuticals NASDAQ:CRNX for a total equity value of about $10 billion, the companies said on Monday.
Vertex Pharmaceuticals Sees Crinetics Deal Helping Non-GAAP Operating Income in 2029 >VRTX
